This is the authors' abstract. We don't add key points for this paper.
Purpose: To evaluate early versus late immunomodulatory therapy (IMT) for patients following initial diagnosis of Vogt-Koyanagi-Harada (VKH) disease. Methods:Retrospective review including all VKH patients seen 5/1/2014 to 4/1/2016 at LAC+USC.Early IMT was defined as starting an immunomodulatory agent within 3 months of corticosteroid initiation.Results: Twenty-seven patients were included, of whom 15 received early IMT and 8 received late IMT.Early IMT patients trended toward greater improvement in vision compared to late IMT (logMAR 0.59 vs. 0.11; p=0.14) with no differences in ocular complications including ocular hypertension (p=0.53) and cataract (p=1.0).Patients receiving early IMT averaged 0.93 recurrences versus 2.13 recurrences for late IMT (p=0.092).Of patients successfully taper off oral corticosteroids, the early IMT group was tapered in an average of 8.3 months versus 19.8 months for late IMT (p=0.0019). Conclusions:Early IMT in VKH may allow for shorter duration of corticosteroids with similar visual outcomes, ocular complications, and disease recurrences.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Storey et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: